Positive data for baricitinib for alopecia areata patients in two phase 3 studies

Results from two 36 weeks studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups (2mg and 4 mg once daily) vs placebo

Biospace Inc.